Back to News
Oct 15, 2025 4:00 PM

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Johnson & Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.

The company posted adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75. The pharmaceutical and medtech giant reported sales of $23.99 billion, up 6.8% year over year and beating the consensus of $23.74 billion. Operational growth was 5.4%, and adjusted operational growth was 4.4%.

Johnson & Johnson affirmed its fiscal year 2025 adjusted earnings guidance of $10.80-$10.90, compared to the consensus of $10.87. Johnson & Johnson raised sales guidance from $93.2 billion-$93.6 billion to $93.5 billion-$93.9 billion compared to the consensus of $93.44 billion.

Johnson & Johnson on Tuesday said it plans to ...